GIUSEPPE MANCIA (0000-0003-0942-3176)

Personal information

Biography

Giuseppe Mancia
Emeritus Professor of Medicine, University of Milano-Bicocca, Milan, Italy.
Giuseppe Mancia is Professor Emeritus at the University Milano-Bicocca, after serving for 20 years as Chairman of the Division and Department of Internal Medicine at the same university at the San Gerardo Hospital in Monza and Director of the Interuniversity (Universities of Milano, Milano-Bicocca, and Pavia) Center for Clinical Physiology and Hypertension. He was Chairman (2001, 2003, 2005, 2007, 2009, 2011, 2013, and 2017) of the Scientific and Organizing Committee of ESH meetings, and is a past President of the International Society of Hypertension (ISH), European Society of Hypertension (ESH), European Society of Clinical Investigation, and Italian Society of Hypertension. He chaired the Task Force of the ESH/ESC Hypertension Guidelines in 2003, 2007, 2009, 2013 and 2018. Professor Mancia is currently Chairman of the ESH Foundation. He is an honorary member of several hypertension and cardiovascular societies and has received many awards, including the Excellence Research Award of AHA, the Heymans Award of the International Society of Pharmacology, the Volhard and Tigersted Awards of the ISH, the Folkow Award of the ESH, the International Recordati Prize, the Invernizzi Prize for Medicine, the Spinoza Honorary Professorship of the University of Amsterdam, the Gold Medal of the Lorenzini Foundation, an Honorary Professorship of the University of Córdoba, an Honoris Causa Doctorate in Medicine from the University of Gdansk, Bucharest (Carol Davila), and Glasgow, the Hariri Memorial Lecture and Award, the MacDonald Award of McMaster University (Hamilton) and the Cleveland Clinic Lecture. Professor Mancia’s research focuses on the epidemiology, pathophysiology, diagnosis, and treatment of hypertension, heart failure, coronary and other cardiovascular diseases. He has edited more than 20 books on hypertension and cardiovascular diseases and published more than 2400 articles in peer review international journals. His articles have received more than 240,000 citations (H-index 182, Microsoft Academics, December 2021).He has been Deputy and Chief Editor of the Journal of Hypertension (1995-2021)

Activities

Collapse all

Effects of valsartan vs amlodipine and achieved lower blood pressure on the incidence of end-stage kidney disease: The VALUE Trial

European Journal of Internal Medicine

2025-03 | Journal article

DOI: 10.1016/j.ejim.2024.12.021

Contributors: Eirik Olsen; Kenneth Jamerson; Roland E. Schmieder; Camilla L. Søraas; Julian E. Mariampillai; Giuseppe Mancia; Sverre E. Kjeldsen; Sondre Heimark; Maria H. Mehlum; Knut Liestøl et al.

GIUSEPPE MANCIA

https://orcid.org/0000-0003-0942-3176

Personal information

Emails & domains

Verified email domains

Biography

Activities

Works (45)

Effects of valsartan vs amlodipine and achieved lower blood pressure on the incidence of end-stage kidney disease: The VALUE Trial

Management of “Elevated” Blood Pressure According to the 2024 European Society of Cardiology Guidelines: Lack of Supportive Evidence and High Risk of Excessive Treatment

Reproducibility and Treatment Effect on Office and Ambulatory Pressure Relation

Adherence to perindopril/amlodipine/atorvastatin combination according to the administration strategy

Lipids and apolipoproteins and the risk of vascular disease and mortality outcomes in women and men with type 2 diabetes in the ADVANCE study

Highlights of the 2023 European Society of Hypertension Guidelines: what has changed in the management of hypertension in patients with cardiac diseases?

Should treatment of ‘elevated’ blood pressure, especially in older people, be based on global risk estimation?

Habitual Regular Coffee Consumption and Arterial Stiffness: Data From the 3rd Pamela Survey

Blood pressure control in the hypertensive population. Factors involved and perspectives

Risk prediction by ambulatory blood pressure monitoring in non-diabetic and diabetic patients: better than office measurements

Cardiovascular Outcomes in Hypertension-Treated Patients With Peripheral Artery Disease: The VALUE Trial

Rationale for the Inclusion of β-Blockers Among Major Antihypertensive Drugs in the 2023 European Society of Hypertension Guidelines

A European Renal Association (ERA) synopsis for nephrology practice of the 2023 European Society of Hypertension (ESH) Guidelines for the Management of Arterial Hypertension

Triglyceride-glucose index, low-density lipoprotein levels, and cardiovascular outcomes in chronic stable cardiovascular disease: results from the ONTARGET and TRANSCEND trials

Randomized Clinical Outcome Trials in Hypertension

TIME to face the reality about evening dosing of antihypertensive drugs in hypertension

Late outcomes of renal denervation are more favourable than early ones: facts or fancies?

Clinical event reductions in high-risk patients after renal denervation projected from the global SYMPLICITY registry

Middle-Aged and Older Patients With Left Ventricular Hypertrophy: Higher Mortality With Drug Treated Systolic Blood Pressure Below 130 mm Hg

Outcomes Following Radiofrequency Renal Denervation According to Antihypertensive Medications: Subgroup Analysis of the Global SYMPLICITY Registry DEFINE

Impact of the Increase in Left Ventricular Mass on the Risk of Long-Term Cardiovascular Mortality: A Prospective Cohort Study

HyperChildNET: A European Network Moving Forward in the Field of Pediatric Hypertension

Clinical Utility of Short-Term Blood Pressure Measures to Inform Long-Term Blood Pressure Management

Effects of Renal Denervation on Sympathetic Nerve Traffic and Correlates in Drug-Resistant and Uncontrolled Hypertension: A Systematic Review and Meta-Analysis

Diverse pharmacological properties, trial results, comorbidity prescribing and neural pathophysiology suggest European hypertension guideline downgrading of beta-blockers is not justified

Harmonization of the American College of Cardiology/American Heart Association and European Society of Cardiology/European Society of Hypertension Blood Pressure/Hypertension Guidelines

Harmonization of the American College of Cardiology/American Heart Association and European Society of Cardiology/European Society of Hypertension Blood Pressure/Hypertension Guidelines

Research strategies in treatment of hypertension: value of retrospective real-life data

Harmonization of the American College of Cardiology/American Heart Association and European Society of Cardiology/European Society of Hypertension Blood Pressure/Hypertension Guidelines: Comparisons, Reflections, and Recommendations

Individualized Beta-Blocker Treatment for High Blood Pressure Dictated by Medical Comorbidities: Indications Beyond the 2018 European Society of Cardiology/European Society of Hypertension Guidelines

Insights From Matched Office and Ambulatory Blood Pressure in Youth: Clinical Relevance

Central and peripheral sympathetic activation in heart failure

White-Coat Hypertension Without Organ Damage: Impact on Long-Term Mortality, New Hypertension, and New Organ Damage

Methodological Aspects of Meta-Analyses Assessing the Effect of Blood Pressure–Lowering Treatment on Clinical Outcomes

Statin treatment reduces the risk of death among elderly frail patients: evidence from a large population-based cohort

White-Coat Hypertension: Pathophysiological and Clinical Aspects: Excellence Award for Hypertension Research 2020

Sympathetic Neural Mechanisms Underlying Attended and Unattended Blood Pressure Measurement

Adherence to Treatment by Initial Antihypertensive Mono and Combination Therapies

Missing Verification of Source Data in Hypertension Research: The HYGIA PROJECT in Perspective

Short- and Long-Term Reproducibility of Nighttime Blood Pressure Phenotypes and Nocturnal Blood Pressure Reduction

COVID-19, hypertension, and RAAS blockers: the BRACE-CORONA trial

Salt and cardiovascular disease: insufficient evidence to recommend low sodium intake

Antihypertensive Treatment in Elderly Frail Patients

Effectiveness of two‐drug therapy versus monotherapy as initial regimen in hypertension: A propensity score‐matched cohort study in the UK Clinical Practice Research Datalink

White-Coat Hypertension: the Neglected Subgroup in Hypertension

Peer review (2 reviews for 1 publication/grant)